P-21 (Adamantane)

P-21 (Adamantane) is a chemically modified research variant within the CNTF-mimetic small-molecule peptide class, incorporating an adamantane cage structure — a rigid, highly lipophilic hydrocarbon moiety widely used in medicinal chemistry to increase metabolic stability and blood-brain-barrier permeability of small peptide and peptidomimetic scaffolds. The base pharmacophore this analog derives from (P021/P21) was designed to mimic ciliary neurotrophic factor (CNTF) signaling in a smaller, blood-brain-barrier-permeable format, engaging the CNTFR-alpha/gp130/LIFR receptor complex and downstream JAK/STAT3 signaling implicated in neuronal survival and synaptic plasticity.

Because the adamantane-conjugated variant is a structural modification rather than a separately characterized clinical candidate, published pharmacology specific to this exact analog is limited; the cited research below pertains to the parent CNTF-mimetic pharmacophore class from which this modified compound is derived, not to adamantane-conjugated P21 specifically. Researchers should treat structure-activity claims for this variant as inferred from the parent scaffold rather than independently validated.

Potential Research Applications: - Structure-activity relationship (SAR) studies of CNTF-mimetic pharmacophores - Blood-brain-barrier permeability and metabolic stability optimization research - CNTFR-alpha/gp130/LIFR receptor complex signaling studies - Comparative neurotrophic factor mimetic research alongside unmodified P21

Market Context: This adamantane-modified variant is currently listed by 1 supplier on this platform (Pure Health Peptides, approximately $119/mg) — a premium reflecting the added synthesis complexity of the adamantane conjugation step relative to unmodified P21, which is more broadly available (see the platform's separate P21 listing for multi-supplier pricing comparison).

Cited Research (parent CNTF-mimetic pharmacophore class): Kazim SF, Iqbal K (2016). Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. PMID 27400746. Wei W, Liu Y (2021). Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction. J Alzheimers Dis. PMID 34057082.

For laboratory research only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.